​

Karyopharm Therapeutics Ownership | Who Owns Karyopharm Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Karyopharm Therapeutics Ownership Summary

Karyopharm Therapeutics is owned by 6.41% institutional investors, 6.60% insiders, and 86.99% retail investors. T. rowe price investment management is the largest institutional shareholder, holding 8.13% of KPTI shares. T. Rowe Price Small-Cap Value is the top mutual fund, with 5.13% of its assets in Karyopharm Therapeutics shares.

KPTI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockKaryopharm Therapeutics6.41%6.60%86.99%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
T. rowe price investment management700.99K8.13%$4.58M
Adage capital partners gp421.32K4.89%$2.76M
Vanguard group408.22K4.74%$2.67M
Blackrock4.17M3.61%$3.62M
Blackrock funding, inc. /de231.95K2.69%$1.52M
Catalio capital management, lp142.98K1.66%$935.12K
Avidity partners management lp134.57K1.56%$880.06K
Marshall wace, llp128.45K1.49%$840.07K
C worldwide group100.00K1.16%$654.00K
Geode capital management93.29K1.08%$610.25K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Birchview capital, lp419.83K0.23%$283.93K
Avidity partners management lp134.57K0.20%$880.06K
Catalio capital management, lp142.98K0.17%$935.12K
Silverback asset management40.00K0.03%$261.60K
Ikarian capital27.26K0.02%$178.26K
Adar1 capital management25.00K0.02%$163.50K
C worldwide group100.00K0.01%$654.00K
Gsa capital partners llp14.08K0.01%$92.00K
Xtx topco14.40K0.00%$94.19K
Bridgeway capital management34.87K0.00%$228.07K

Top Buyers

HolderShares% AssetsChange
Susquehanna group, llp664.14K0.00%361.60K
Alyeska investment group144.51K0.00%144.51K
Bank of america corp /de/298.69K-140.77K
Adar1 capital management25.00K0.02%25.00K
Baird financial group25.93K0.00%15.40K

Top Sellers

HolderShares% AssetsChange
Blackrock4.17M0.00%-5.28M
Exome asset management---2.00M
Opaleye management---1.43M
Deutsche bank ag\---1.27M
Kennedy capital management---1.20M

New Positions

HolderShares% AssetsChangeValue
Adar1 capital management25.00K0.02%25.00K$163.50K
Belvedere trading14.56K0.00%14.56K$95.24K
Rise advisors131.000.00%131.00$857.00
Pittenger & anderson3.00-3.00$20.00

Sold Out

HolderChange
Zurcher kantonalbank (zurich cantonalbank)-6.00
Farther finance advisors-13.00
Nelson, van denburg & campbell wealth management group-22.00
Financial gravity asset management-50.00
Nisa investment advisors-50.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202518-62.50%552,924-86.33%60.29%5-79.17%3-50.00%
Jun 30, 2025524.00%4,384,528-15.32%50281.78%27575.00%7-83.33%
Mar 31, 202551-45.74%5,312,129-91.28%40.17%4-88.89%4386.96%
Dec 31, 202492-4.17%60,468,4381.78%482.14%3413.33%24-22.58%
Sep 30, 202496-20.00%59,409,677-12.02%471.39%31-41.51%31-6.06%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
T. Rowe Price Small-Cap Value445.26K5.13%-1.02K
T. Rowe Price U.S. SC Value Eq Tr-D263.68K3.05%213.59K
Vanguard US Total Market Shares ETF3.42M2.71%-1.00
Vanguard Total Stock Mkt Idx Inv223.22K2.58%-4.88K
Vanguard Explorer Inv133.88K1.55%-
C WorldWide Healthcare Select 1A100.00K1.16%-
Vanguard Institutional Extnd Mkt Idx Tr80.72K0.93%-36.78K
AlphaCentric LifeSci Healthcare I1.13M0.90%-
AlphaCentric Life Sciences & Hlthcare I1.13M0.89%-
Kennedy Micro Cap1.03M0.81%-22.77K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 01, 2025Abate Kristin Chief Accounting OfficerSell$2.28K
Sep 15, 2025Paulson Richard A. President and CEOSell$8.08K
Sep 15, 2025Mano Michael SVP, General Counsel&SecretarySell$1.50K
Sep 15, 2025Poulton Stuart EVP, Chief Development OfficerSell$2.58K
Sep 15, 2025Rangwala Reshma EVP & Chief Medical OfficerSell$2.62K

Insider Transactions Trends

DateBuySell
2025 Q4-1
2025 Q3-9
2025 Q2-3
2025 Q1-4
2024 Q4-3

KPTI Ownership FAQ

Who Owns Karyopharm Therapeutics?

Karyopharm Therapeutics shareholders are primarily institutional investors at 6.41%, followed by 6.60% insiders and 86.99% retail investors. The average institutional ownership in Karyopharm Therapeutics's industry, Biotech Stocks , is 45.24%, which Karyopharm Therapeutics falls below.

Who owns the most shares of Karyopharm Therapeutics?

Karyopharm Therapeutics’s largest shareholders are T. rowe price investment management (700.99K shares, 8.13%), Adage capital partners gp (421.32K shares, 4.89%), and Vanguard group (408.22K shares, 4.74%). Together, they hold 17.76% of Karyopharm Therapeutics’s total shares outstanding.

Does Blackrock own Karyopharm Therapeutics?

Yes, BlackRock owns 3.61% of Karyopharm Therapeutics, totaling 4.17M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.62M$. In the last quarter, BlackRock decreased its holdings by -5.278M shares, a -55.86% change.

Who is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested?

Birchview capital, lp is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.23% of its assets in 419.83K Karyopharm Therapeutics shares, valued at 283.93K$.

Who is the top mutual fund holder of Karyopharm Therapeutics shares?

T. Rowe Price Small-Cap Value is the top mutual fund holder of Karyopharm Therapeutics shares, with 5.13% of its total shares outstanding invested in 445.26K Karyopharm Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools